Suppr超能文献

使用P28肽制剂增强用于骨再生的支架体内生物降解性

Enhancement of Scaffold In Vivo Biodegradability for Bone Regeneration Using P28 Peptide Formulations.

作者信息

Azaman Farah Alwani, Brennan Fournet Margaret E, Sheikh Ab Hamid Suzina, Zawawi Muhamad Syahrul Fitri, da Silva Junior Valdemiro Amaro, Devine Declan M

机构信息

PRISM Research Institute, Technological University of the Shannon (TUS), N37 HD68 Athlone, Ireland.

Tissue Bank, School of Medical Sciences, Health Campus, Universiti Sains Malaysia (USM), 16150 Kota Bharu, Malaysia.

出版信息

Pharmaceuticals (Basel). 2023 Jun 13;16(6):876. doi: 10.3390/ph16060876.

Abstract

The field of bone tissue engineering has shown a great variety of bone graft substitute materials under development to date, with the aim to reconstruct new bone tissue while maintaining characteristics close to the native bone. Currently, insufficient scaffold degradation remains the critical limitation for the success of tailoring the bone formation turnover rate. This study examines novel scaffold formulations to improve the degradation rate in vivo, utilising chitosan (CS), hydroxyapatite (HAp) and fluorapatite (FAp) at different ratios. Previously, the P28 peptide was reported to present similar, if not better performance in new bone production to its native protein, bone morphogenetic protein-2 (BMP-2), in promoting osteogenesis in vivo. Therefore, various P28 concentrations were incorporated into the CS/HAp/FAp scaffolds for implantation in vivo. H&E staining shows minimal scaffold traces in most of the defects induced after eight weeks, showing the enhanced biodegradability of the scaffolds in vivo. The HE stain highlighted the thickened periosteum indicating a new bone formation in the scaffolds, where CS/HAp/FAp/P28 75 µg and CS/HAp/FAp/P28 150 µg showed the cortical and trabecular thickening. CS/HAp/FAp 1:1 P28 150 µg scaffolds showed a higher intensity of calcein green label with the absence of xylenol orange label, which indicates that mineralisation and remodelling was not ongoing four days prior to sacrifice. Conversely, double labelling was observed in the CS/HAp/FAp 1:1 P28 25 µg and CS/HAp/FAp/P28 75 µg, which indicates continued mineralisation at days ten and four prior to sacrifice. Based on the HE and fluorochrome label, CS/HAp/FAp 1:1 with P28 peptides presented a consistent positive osteoinduction following the implantation in the femoral condyle defects. These results show the ability of this tailored formulation to improve the scaffold degradation for bone regeneration and present a cost-effective alternative to BMP-2.

摘要

迄今为止,骨组织工程领域已研发出种类繁多的骨移植替代材料,旨在重建新的骨组织,同时保持接近天然骨的特性。目前,支架降解不足仍是调整骨形成周转率成功与否的关键限制因素。本研究检测了新型支架配方,以提高其在体内的降解率,该配方使用了不同比例的壳聚糖(CS)、羟基磷灰石(HAp)和氟磷灰石(FAp)。此前有报道称,P28肽在促进体内成骨方面,即使不比其天然蛋白骨形态发生蛋白-2(BMP-2)更好,也表现出相似的新骨生成性能。因此,将不同浓度的P28掺入CS/HAp/FAp支架中用于体内植入。苏木精-伊红(H&E)染色显示,在八周后诱导的大多数缺损中,支架痕迹极少,表明支架在体内的生物降解性增强。HE染色突出了增厚的骨膜,表明支架中有新骨形成,其中CS/HAp/FAp/P28 75 μg和CS/HAp/FAp/P28 150 μg显示出皮质和小梁增厚。CS/HAp/FAp 1:1 P28 150 μg支架显示钙黄绿素绿色标记强度较高,且没有二甲苯酚橙标记,这表明在处死前四天没有进行矿化和重塑。相反,在CS/HAp/FAp 1:1 P28 25 μg和CS/HAp/FAp/P28 75 μg中观察到双标记,这表明在处死前第10天和第4天持续有矿化。基于HE和荧光染料标记,含P28肽的CS/HAp/FAp 1:1在植入股骨髁缺损后呈现出一致的阳性骨诱导作用。这些结果表明,这种定制配方能够改善用于骨再生的支架降解,并提供一种比BMP-2更具成本效益的替代方案。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a86d/10304976/ff8c6ba9b3b0/pharmaceuticals-16-00876-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验